Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Ticagrelor after fibrinolytic therapy in patients younger than 75 years with STEMI may not reduce ...

(UPDATED) The varying severity of COVID-19 “surges” around the United States to date has left cath labs debating whether to switch to fibrinolytic-based strategies for STEMI patients, or continue to ...

Please provide your email address to receive an email when new articles are posted on . A strategy involving a reduced dose of fibrinolytic agents plus urgent PCI was associated with improved survival ...

When opting for a reperfusion strategy for STEMI that includes fibrinolytics, fibrin-specific agents combined with parenteral anticoagulants are the best choice, a network meta-analysis affirms.

Linköping and Uppsala, Sweden - An investigation of one-year mortality and bleeding complications associated with fibrinolytic therapy in patients over age 75 suggests that the drugs reduce deaths and ...

Dennis T. Ko, M.D. However, a significant proportion of STEMI patients will "fail" to reperfuse following fibrinolytic therapy; indeed, normal coronary blood flow (TIMI flow grade 3) is achieved in ...

ORLANDO -- Among younger ST-segment elevation MI (STEMI) patients who can't get primary angioplasty in time, and wind up getting fibrinolytics as the main reperfusion therapy, subsequent ticagrelor ...

You have full access to this article via your institution. The Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis In Myocardial Infarction study (CLARITY-TIMI) 28 trial was an international, ...

New guidelines published online today in Circulation and the Journal of the American College of Cardiology provide an efficient overview of the best treatments for STEMI patients. (Click here to ...

In spite of an increased attention to gender differences in treatment of myocardial infarctions, focus on adherence to guidelines and a change in predominant therapy, the gender difference in ...

Lead augmented vector right (aVR) is a useful measure in the diagnosis of ST-segment elevation acute myocardial infarction (STEMI), indicates a new analysis of data from the HERO-2 trial. “Lead aVR is ...